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Gut microbiota influences host health status by
providing trophic, protective, and metabolic func-
tions, including bile acid (BA) biotransformation.
Microbial imprinting on BA signature modifies pool
size and hydrophobicity, thus contributing to BA
enterohepatic circulation. Microbiota-targeted ther-
apies are now emerging as effective strategies for
preventing and/or treating gut-related diseases.
Here, we show that gut microbiota modulation in-
duced by VSL#3 probiotics enhances BA deconjuga-
tion and fecal excretion in mice. These events are
associated with changes in ileal BA absorption,
repression of the enterohepatic farnesoid X recep-
tor-fibroblast growth factor 15 (FXR-FGF15) axis,
and increased hepatic BA neosynthesis. Treatment
with a FXR agonist normalized fecal BA levels in
probiotic-administered mice, whereas probiotic-
induced alterations in BA metabolism are abolished
upon FXR and FGF15 deficiency. Our data provide
clear in vivo evidence that VSL#3 probiotics promote
ileal BA deconjugation with subsequent fecal BA
excretion and induce hepatic BA neosynthesis via
downregulation of the gut-liver FXR-FGF15 axis.INTRODUCTION
The human gastrointestinal tract is home to a complex and
dynamic microbial ecosystem containing tens of trillions of
microorganisms and encoding at least 150-fold more genes
than the human genome (Gareau et al., 2010; Leser and
Mølbak, 2009). The gut microbial community is instrumental
in host energy metabolism and immune functions and greatly
contributes to a wide range of processes including protection
against pathogens, vitamin synthesis and ion absorption,
carbohydrate and protein fermentation, bile acid (BA) biotrans-
formation, and immune system modulation (Guarner and Mala-
gelada, 2003; Hamer et al., 2012; Kinross et al., 2008; Ridlon12 Cell Reports 7, 12–18, April 10, 2014 ª2014 The Authorset al., 2006; Round and Mazmanian, 2009; Tsai and Coyle,
2009).
Composition of gut microbiota is modulated by numerous
extrinsic factors such as diet, age, medication, and stress. Dis-
turbances of gut microbiota, also known as dysbiosis, have often
been associated with several diseases including inflammatory
bowel disease (IBD), obesity, type 2 diabetes, and cancer
(Muegge et al., 2011). Accumulating evidence indicates that
gut microbiota composition is readily changeable and, accord-
ingly, that the plasticity of microbiome favors the development
of gut microbiota-targeted therapy including antibiotics, prebi-
otics, and probiotics. Probiotics are live microorganisms that
provide beneficial effects to the host when adequately adminis-
tered, and their therapeutic potential has been documented in
the maintenance treatment of ulcerative colitis, pouchitis, and
IBD (Jijon et al., 2004; Gionchetti et al., 2000).
The integrated metabolism of the BA pools is a good example
of the complex transgenomic biochemical interactions between
host and enteric microbiome symbionts (Turroni et al., 2008). Pri-
mary BAs, cholic acid (CA), and chenodeoxycholic acid (CDCA)
in humans (beta-muricholic acid [b-MCA] inmice) are sterol com-
pounds synthesized from cholesterol in the liver, conjugatedwith
taurine and glycine, and then secreted into the small intestine.
During the transit to the large intestine, primary BAs undergo
deconjugation, oxidation of hydroxyl groups at C-3, C-7, and
C-12, and 7a/b-dehydroxylation reactions mediated by enteric
anaerobic bacteria enzymes, yielding secondary BAs such as
deoxycholic acid (DCA), lithocholic acid (LCA), and b-muri-deox-
ycholicacid (bMDCA) (Begley et al., 2006; Lefebvre et al., 2009;
Patel et al., 2010; Ridlon et al., 2006). Bile salt hydrolase (BSH)
catalyzes the ‘‘gateway’’ reaction in the bacterial metabolism
of conjugated BAs and is a prerequisite for the subsequent
7a/b-dehydroxylation (Batta et al., 1990; Jones et al., 2008).
BA pool size and composition are strongly influenced by gut
microbiota, and BA biotransformation has important biological
consequences; indeed, BAs participate in the regulation of die-
tary lipid absorption and act as signaling molecules, modulating
cholesterol and triglyceride metabolism and glucose and energy
homeostasis (Houten et al., 2006; Ridlon et al., 2006).
Previous animal studies have reported that changes in BA
signature were associated with both acute (i.e., antibiotic treat-
ment) and chronic (germ-free condition) gut microbiota depletion
Figure 1. Colonization of Gut Microbiota with Probiotic Bacteria Enhances Fecal BA Excretion and BA Deconjugation
Phylum- (A) and family- and genus- (B) level modifications of fecal microbiota upon VSL#3 treatment are shown as mean percentage of the total sequences.
(C) Mice receiving VSL#3 (filled squares) exhibited increased fecal BA excretion compared to vehicle-treated mice (open circles). Data points represent means ±
SEM (n = 6 mice/group for each time point). Although the fecal CA/DCA ratio (D) was unchanged, the conjugated/unconjugated BA ratio (E) decreased in VSL#3
mice (black bars) compared to vehicle (white bars). These metabolic changes were associated with increased fecal BSH expression (F) and enzyme activity (G) in
mice receiving probiotic bacteria with L. acidophilus and B. infantis displaying much higher BSH activity compared to S. thermophilus (H). An asterisk indicates
significant differences between groups (p < 0.05).(Claus et al., 2008; Martin et al., 2007; Wostmann, 1973; Swann
et al., 2011) and linked to the development of diet-induced
dysbiosis (Devkota et al., 2012). Although CA has been identi-
fied as a host factor regulating composition of cecal microbiota
(Islam et al., 2011), recent mouse studies have suggested a
direct connection between FXR function and gut microbiota
(Sayin et al., 2013; Hu et al., 2014). Moreover, levels of tauro-
b-muricholic acid (TbMCA) have recently been associated
with alterations of the FXR signaling pathway together with
Lactobacillus abundance and bile-acid-deconjugating activity
in feces (Li et al., 2013). Nevertheless, it is unclear whether
colonization of gut microbial community with lactic-acid-
producing bacteria (namely probiotics) can modify BA pool
size and composition thus influencing BA enterohepatic circu-
lation. In this study, we provide evidence that probiotic
modulation of gut microbiota composition increases fecal BAdeconjugation and excretion along with induction of hepatic
BA neosynthesis.
RESULTS
VSL#3 Administration Modifies Gut Microbiota while
Enhancing BA Deconjugation and Fecal Excretion
We first explored the phylum-, family-, and genus-level modifi-
cations of gut microbiota upon VSL#3 mixture administration.
The bacterial population of vehicle-treated mice in our animal
facility was dominated by Bacteroidetes (60.1%) and Firmicutes
(37%) with minor populations such as Proteobacteria (2.36%).
Twenty-one day administration of VSL#3 resulted in a signifi-
cantly higher abundance of Firmicutes (51.47%) and Actinobac-
teria (3.31%) at the expense of Bacteroidetes (44.22%) and
Proteobacteria (1%) (Figure 1A). Significant expansion of theCell Reports 7, 12–18, April 10, 2014 ª2014 The Authors 13
Figure 2. VSL#3 Probiotics Influence Ileal BA
Absorption without Modifying Asbt Function
(A) ASBT mRNA.
(B) Protein levels.
(C) Metabolic flux study was performed to assess
ileal [3H]-TCA absorption in vehicle and VSL#3-
treated mice.
(D) Ileal Osta, Ostb, and Ibabp expression level.
Data are expressed as means ± SEM (n = 6 mice/
group). Cyclophillin was used as a housekeeping
gene to normalize data and vehicle-treated mice
were used as calibrators. An asterisk indicates sig-
nificant differences between groups (p < 0.05).Streptococcaceae, Bifidobacteriaceae, and Lactobacillaceae
families, at the expense of Prevotellaceae, contributed to
the higher abundance of Firmicutes and Actinobacteria (Fig-
ure 1B) in VSL#3-treated mice. Moreover, within the afore-
mentioned families, the increased percentage of sequences
attributed to the genus Streptococcus, Lactobacillus, and
Bifidobacterium indicated that 21 day treatment with VSL#3
was sufficient to colonize gut microbiota with probiotic
bacteria, as previously reported by Pagnini et al. (2010). Enteric
bacterial enzymes shape BA pool size and composition by
mediating deconjugation and 7a-dehydroxylation of primary
BAs. To study the extent of BA biotransformation upon probi-
otic colonization, we measured fecal BA excretion and com-
position. VSL#3 administration enhanced fecal BA loss
(Figure 1C) while leaving the fecal CA/DCA ratio unchanged
(Figure 1D) and decreasing the fecal conjugated/unconjugated
BA ratio (Figure 1E). These metabolic changes in fecal BA
composition (Table S1) were accompanied by a significant
increase of both BSH transcript (Figure 1F) and enzymatic
activity (Figure 1G) in the feces collected from VSL#3-treated
mice. The BA-deconjugating ability of probiotic bacteria, mostly
Lactobacilli and Bifidobacteria, has been extensively docu-
mented (Begley et al., 2006; Tanaka et al., 1999; Tannock
et al., 1989). To explore whether the increased fecal BSH
activity measured in VSL#3-treated mice was conferred by
the bacterial strains contained in the VSL#3 mixture, three
representative strains, namely, L. acidophilus, B. infantis, and
S. thermophilus were cultured and assessed for BSH activity.
As shown in Figure 1H, BSH activity was detected in both
L. acidophilus and B. infantis but not in S. thermophilus. Finally,
it has been reported that probiotic strains do not exhibit 7a-de-
hydroxylase activity (Takahashi and Morotomi, 1994); accord-
ingly, the fecal CA/DCA ratio was similar between treatment
groups (Figure 1D).14 Cell Reports 7, 12–18, April 10, 2014 ª2014 The AuthorsVSL#3-Mediated Enhanced Fecal
Loss Is Independent from Asbt
Enhanced fecal BA loss has been reported
when ileal BA absorption is disrupted
(Dawson et al., 2003) or in the case of so-
called ‘‘malabsorption syndrome’’ as ob-
served in humans (Oelkers et al., 1997). In
order to exploit the molecular mechanism
by which VSL#3-treated animals displayed
higher levels of fecal BA, we measured themRNA and protein levels of the apical sodium bile acid trans-
porter (ASBT), responsible for the ileal BA uptake with a prefer-
ence for conjugated over unconjugated BAs (Alrefai and Gill,
2007; Craddock et al., 1998). As shown in Figures 2A and 2B,
no differences between vehicle and VSL#3-treated animals
were detected in either AsbtmRNA or protein levels. We then hy-
pothesized that, even in the presence of unchanged ASBT levels,
VSL#3 treatment might modify intraluminal and transepithelial
BA transport. As illustrated in Figure 2C, mice receiving VSL#3
displayed an increased intraluminal retention of radiolabeled
[3H]-TCA, which was paralleled by decreased absorption, serum
disposal, and biliary secretion as shown by the lower radiola-
beled content in the gallbladder. These findings were associated
with an appreciable reduction in mRNA levels of bile acid trans-
porters (organic solute transporter alpha and beta, Osta and
Ostb and the ileal bile acid binding protein Ibabp) relevant to
both ileal intracellular binding and basolateral secretion into
portal circulation (Figure 2D).
VSL#3 Treatment Impacts BA Enterohepatic Circulation
and Induces Cyp7a1 and Cyp8b1 Expression Levels in
the Liver
Along with the VSL#3-mediated increase in fecal BA excretion,
gallbladder BA and TCA/TbMCA ratio also increased (Figures
3A and 3B, Table S1), whereas no differences were measured
in hepatic BA content (Figure 3C). Small intestine luminal BA con-
tent was higher upon VSL#3 treatment, presumably as a result of
increased biliary output (Figure 3D). Finally, BA pool size and
serum levels appeared unchanged (Figures 3E and 3F). It has
been previously reported that enhanced fecal BA loss, either
driven by ASBT genetic deletion or induced by BA sequestrant
administration, is accompanied by enhanced hepatic BA neo-
synthesis (Dawson et al., 2003; Herrema et al., 2010; Jung
et al., 2007; Out et al., 2011). As indicated in Figure 3G,
Figure 3. VSL#3 Probiotics Modify BA Homeostasis and Induce Hepatic BA Synthesis via Fxr-Fgf15 Axis Downregulation
(A–F) Bile acid (A) and TCA/TbMCA ratio (B) in gallbladder bile were increased upon VSL#3 treatment. BA content in liver (C), small intestine lumen (D), pool
size (E), and serum (F).
(G and H) Hepatic (G) and ileal (H) gene expression profile in vehicle and VSL#3-treated mice.
Data are expressed asmeans ± SEM (n = 6mice/group). Cyclophillin was used as a housekeeping gene to normalize data, and vehicle-treatedmice were used as
calibrators. An asterisk indicates significant differences between groups (p < 0.05 and p < 0.01). Bsep, bile salt export pump; Cyp7a1, cholesterol-7alpha-hy-
droxylase; Cyp8b1, sterol-12alpha-hydroxylase; Fgf15, fibroblast growth factor 15; Fxr, farnesoid X receptor; Lrh1, liver receptor homolog- 1; Ntcp, sodium-
dependent taurocholic-cotransporting polypeptide; Shp, small heterodimer partner; TCA, tauro-cholic acid; TbMCA, tauro-b-muricholic acid.VSL#3-treated mice exhibited increased mRNA levels of choles-
terol-7a-hydroxylase (Cyp7a1) and sterol-12a-hydroxylase
(Cyp8b1), rate-limiting enzymes in BA synthesis (Chiang, 2009;
Jelinek et al., 1990; Schwarz et al., 2001). BA synthesis is tightly
regulated, and the feedback suppression ofCyp7a1 andCyp8b1
gene transcription by the farnesoid X receptor (Fxr) is the one of
most important mechanisms in the maintenance of BA homeo-
stasis (Sinal et al., 2000). Previous studies have shown that
FXR activation is the major mechanism in BA synthesis suppres-
sion, inducing small heterodimer partner (Shp) and fibroblast
growth factor 15/19 (Fgf15/19), which cooperate to suppress
Cyp7a1 and Cyp8b1 (Goodwin et al., 2000; Inagaki et al., 2005;
Lu et al., 2000). As shown in Figures 3G and 3H, Cyp7a1 and
Cyp8b1 upregulation was driven by repression of the ileal
FGF15 signal with no changes in Shp and liver receptor
homolog-1 (Lrh-1) mRNA levels. These data underline that
reduction in ileal BA absorption via VSL#3 decreased intracel-
lular BA levels with downregulation of FXR transcriptional activ-
ity, as shown by reduction of mRNA levels of its target genes
Fgf15 (Figure 3H), Osta and Ostb, and Ibabp (Figure 2D). More-
over, our findings support the notion that deconjugated BA are
less efficient at being absorbed in the ileum and activating intra-
enterocyte FXR transcriptional machinery compared to conju-
gated ones, as previously reported by Parks et al. (1999). Ofnote, ileal Fxr transcript levels were unaffected by VSL#3 treat-
ment. Finally, in agreement with no changes in BA pool size,
hepatic bile salt export pump (Bsep) and sodium-dependent
taurocholic-cotransporting polypeptide (Ntcp) mRNA levels
were unaltered (Figure 3G).
The Functional FXR/Fgf15 Axis Is Required for
VSL#3-Mediated Increase in Fecal BA Excretion while
FXR Reactivation Normalizes the Phenotype
To fully characterize the role of FXR/FGF15 axis in probiotic-
induced alterations of BA metabolism, we treated FXR-deficient
mice with vehicle or VSL#3. As illustrated in Figures 4A and 4B,
21-day treatment with VSL#3 was sufficient to increase Firmi-
cutes abundance (from 40.47% to 50.04%) at the expense of
Bacteroidetes (from 57.86% to 46.9%) and to determine alter-
ations at family and genus level similar to those found in wild-
type animals (Figures 1A and 1B). Interestingly, enrichment of
gut flora with lactic-acid-producing bacteria was able to lower
colonic pH (from 6.9 to 6.3), as assessed in colonic luminal con-
tents from VSL#3-treated animals (data not shown). To deter-
mine whether FXR deficiency would prevent VSL#3-induced
BA metabolism modifications and to evaluate whether the
VSL#3 phenotype would arise from reduced Fgf15 expression
only (Figure 3H), we measured fecal BA levels in FXR/ andCell Reports 7, 12–18, April 10, 2014 ª2014 The Authors 15
Figure 4. FXR and Fgf15 Deficiency Abolish VSL#3 Probiotic-Mediated Increase of Fecal BA Excretion
(A andB) Phylum- (A), family- and genus- (B) level modifications of fecalmicrobiota of FXR-deficient mice upon VSL#3 treatment are shown as amean percentage
of the total sequences. Data are expressed as means ± SEM (n = 6 mice/group).
(C) Fecal BA excretion in wild-type, FXR-, and Fgf15-deficient mice after 21 days of VSL#3 treatment.Fgf15/ mice that exhibited a constitutive elevated fecal BA
excretion due to hepatic CYP7A1 derepression. In both FXR/
and Fgf15/ animals, fecal BA loss was similar between groups
(Figure 4C). Of note, biliary and fecal BA composition (Table S1)
appeared unmodified by VSL#3 probiotics upon FXR deficiency.
Indeed, no changes in any hepatic or intestinal FXR target genes
were detected in FXR/ mice (Figures S1A and S1B). Collec-
tively, the data suggest that a functional FXR transcriptional
activity is required for VSL#3 probiotic administration to promote
fecal BA excretion and induce hepatic BA neosynthesis. Finally,
to test the hypothesis that reactivation of FXR transcriptional
machinery would normalize the phenotype, we cotreated wild-
typemice with a synthetic FXR agonist (GW4064) for 2 days prior
to necropsy. As indicated in Figure S2, GW4064 was able to
reverse VSL#3-induced alterations in BA levels in feces (Fig-
ure S2A) and intestinal lumen (Figure S2B), whereas leaving
hepatic BA levels unchanged (Figure S2C).
DISCUSSION
Gut microbiota and BA metabolism are mutually linked, as
changes in BA signature as well as modulation of the enterohe-
patic FXR/Fgf15/Cyp7a1 axis are found in germ-free, gnotobi-
otic, and antibiotic-treated animals (Claus et al., 2008; Martin
et al., 2007; Wostmann, 1973; Swann et al., 2011; Sayin et al.,
2013; Hu et al., 2014). Bacterial metabolism mediates primary
BA deconjugation and subsequent conversion to secondary
BAs, is partially responsible for BA fractional turnover rate, deter-
mines the amount of secondary BAs that may be detrimental on16 Cell Reports 7, 12–18, April 10, 2014 ª2014 The Authorscolonic epithelium architecture, and primes BA ability to function
as efficient FXR ligands.
In this report, we show that colonization of gut flora with VSL#3
probiotics, widely employed in the therapeutic management of
IBD, promotes increased BA deconjugation and fecal excretion.
These events are associated with increased hepatic synthesis
and biliary output and repression of the enterohepatic FXR/
Fgf15 axis and, conversely, are reversed upon FXR agonist
administration. We provide evidence that enrichment of gut
flora with the BSH-retaining species (mostly Lactobacilli and
Bifidobacteria) produces significant alterations in BA homeosta-
sis only in the presence of a functional FXR transcriptional activity
because VSL#3 phenotype is abrogated in both FXR/ and
Fgf15/ animals. In agreement with our data, an earlier report
suggested that TCA- or TbMCA-deconjugating bacterial strains
promote an increased fecal BA loss (Chikai et al., 1987) in
germ-free rats compared to those strains that deconjugate
neither (i.e., E. coli). One may hypothesize that, by increasing
BSHactivity and, accordingly, unconjugatedBAcontent in the in-
testinal lumen,VSL#3administrationmaynegatively influenceBA
reuptake thus negatively regulate intraenterocyte FXR transcrip-
tional activity (Parks et al., 1999). Previous studies employing
in situ perfused intestinal segments demonstrated that ileal bile
acid transport is a high-capacity systemaccounting for reabsorp-
tion of biliary BA output and is themajor route for conjugated BAs
(Aldini et al., 1994; Marcus et al., 1991). In our study, AsbtmRNA
and protein levels appeared unaltered by VSL#3 treatment,
whereas, by performing a metabolic flux study using [3H]-TCA,
an increased intraluminal retention of radiolabeled compound
along with significantly reduced levels in the gallbladder (that
might correspond to lower intracellular BA absorption and serum
disposal) were measured. VSL#3 administration by limiting the
availability of efficient FXR ligands (i.e., conjugated BAs) induces
a repression of the FXR/Fgf15 axis thus upregulating the Cyp7a1
and Cyp8b1 genes. Moreover, the metabolic phenotype of
VSL#3-treated mice is reminiscent of the findings of Herrema
et al. (2010) (increases in both fecalBAexcretion andhepatic syn-
thesis with no change in BA pool size) in lean mice receiving the
bile acid sequestrant colesevelam. More importantly, VSL#3-
induced alterations of BA metabolism were abolished in FXR-
and Fgf15-deficient mice thus suggesting that a functional FXR
transcriptional activity is required for probiotic bacteria to pro-
mote fecal BA loss and induce hepatic BA synthesis.
Probiotic formulations are currently employed as therapeutic
options in patients diagnosed with IBD, diarrhea, pouchitis,
and ulcerative colitis. As variations in the gut microbial capacity
for BA modification may be a significant factor in IBD onset or
progression, the ability of VSL#3 to modulate BSH activity could
be relevant in pathological conditions such as colitis, bacterial
translocation secondary to intrahepatic cholestasis, or colon
carcinogenesis.
In summary, the findings of this study expand our current
knowledge of microbiota-induced changes of BA metabolism,
providing evidence that VSL#3 administration enhances fecal
BA excretion and hepatic BA synthesis and requires a functional
FXR/Fgf15 enterohepatic axis.
EXPERIMENTAL PROCEDURES
Animals and Treatments
Wild-typeC57BL/6Jmalemicewere obtained fromCharlesRiver Laboratories.
Wild-type C57BL/6J mice were treated daily with GW4064 (75 mg/kg/body
weight, Sigma-Aldrich) or vehicle (arabic gum) by gavage for 2 days prior to
necropsy. Pure strain C57BL/6J FXR/ and C57BL/6J/129Sv Fgf15/ male
mice and their wild-type littermates were kindly provided byDrs. D.J.Mangels-
dorf and S.A. Kliewer (UT SouthwesternMedical Center, Dallas, TX). Micewere
housed in a temperature-controlled room (22C–23C) under a 12 hr light/12 hr
dark cycle and fed standard rodent chowandwater ad libitum.Micewere given
a daily oral gavage of saline or VSL#3 mixture (50 3 109 cfu/day) for 21 days,
and fecal sampleswere collected tomeasure fecal bile acid excretion, bacterial
gene expression, and enzymatic activity. Total DNA isolated from feces was
used as a template for the amplification of the 16S rRNAV5-V6 region, and sub-
jected toGS-FLXmultiplex pyrosequencing tomeasure the relative abundance
at phylum, family, and genus level between saline- and VSL#3-treated animals
as previously described (De Filippo et al., 2010). After 21 day treatment, the
micewere sacrificed, and tissueswereweighed, snap-frozen in liquid nitrogen,
and stored at 80C until processing. All experiments were approved by the
Ethical Committee of the Fondazione Mario Negri Sud (Chieti, Italy) and certi-
fied by the ItalianMinistry of Health in accordancewith internationally accepted
guidelines for animal care.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.02.032.
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